Mycophenolic Acid Overcomes Imatinib and Nilotinib Resistance of Chronic Myeloid Leukemia Cells by Apoptosis or a Senescent-Like Cell Cycle Arrest
Author(s) -
Claire Drullion,
Valérie Lagarde,
Romain Gioia,
Patrick Legembre,
Muriel Priault,
Bruno Cardinaud,
Éric Lippert,
FrançoisXavier Mahon,
JeanMax Pasquet
Publication year - 2012
Publication title -
leukemia research and treatment
Language(s) - English
Resource type - Journals
eISSN - 2090-3219
pISSN - 2090-3227
DOI - 10.1155/2012/861301
Subject(s) - apoptosis , myeloid leukemia , autophagy , annexin , programmed cell death , k562 cells , nilotinib , imatinib , cancer research , annexin a5 , cell cycle , senescence , biology , microbiology and biotechnology , cell cycle checkpoint , chemistry , biochemistry
We used K562 cells sensitive or generated resistant to imatinib or nilotinib to investigate their response to mycophenolic acid (MPA). MPA induced DNA damage leading to cell death with a minor contribution of apoptosis, as revealed by annexin V labeling (up to 25%). In contrast, cell cycle arrest and positive staining for senescence-associated β -galactosidase activity were detected for a large cell population (80%). MPA-induced cell death was potentialized by the inhibition of autophagy and this is associated to the upregulation of apoptosis. In contrast, senescence was neither decreased nor abrogated in autophagy deficient K562 cells. Primary CD34 cells from CML patients sensitive or resistant to imatinib or nilotinib respond to MPA although apoptosis is mainly detected. These results show that MPA is an interesting tool to overcome resistance in vitro and in vivo mainly in the evolved phase of the disease.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom